GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Woojung Bio Inc (XKRX:215380) » Definitions » EV-to-EBIT

Woojung Bio (XKRX:215380) EV-to-EBIT : 25.33 (As of Jun. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Woojung Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Woojung Bio's Enterprise Value is ₩72,650 Mil. Woojung Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩2,868 Mil. Therefore, Woojung Bio's EV-to-EBIT for today is 25.33.

The historical rank and industry rank for Woojung Bio's EV-to-EBIT or its related term are showing as below:

XKRX:215380' s EV-to-EBIT Range Over the Past 10 Years
Min: -120.08   Med: -7.46   Max: 7790.55
Current: 25.33

During the past 10 years, the highest EV-to-EBIT of Woojung Bio was 7790.55. The lowest was -120.08. And the median was -7.46.

XKRX:215380's EV-to-EBIT is ranked worse than
73.4% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs XKRX:215380: 25.33

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Woojung Bio's Enterprise Value for the quarter that ended in Mar. 2025 was ₩69,600 Mil. Woojung Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩2,868 Mil. Woojung Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 4.12%.


Woojung Bio EV-to-EBIT Historical Data

The historical data trend for Woojung Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Woojung Bio EV-to-EBIT Chart

Woojung Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.60 -87.79 79.31 -40.10 21.68

Woojung Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.71 14.31 13.14 21.68 24.27

Competitive Comparison of Woojung Bio's EV-to-EBIT

For the Biotechnology subindustry, Woojung Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Woojung Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Woojung Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Woojung Bio's EV-to-EBIT falls into.


;
;

Woojung Bio EV-to-EBIT Calculation

Woojung Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=72650.290/2867.631
=25.33

Woojung Bio's current Enterprise Value is ₩72,650 Mil.
Woojung Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,868 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Woojung Bio  (XKRX:215380) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Woojung Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=2867.631/69600.268
=4.12 %

Woojung Bio's Enterprise Value for the quarter that ended in Mar. 2025 was ₩69,600 Mil.
Woojung Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,868 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Woojung Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Woojung Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Woojung Bio Business Description

Traded in Other Exchanges
N/A
Address
Gwanggyo-ro 145, B-dong 3rd Floor, Next Generation Convergence Technology Research Center, Gyeonggi-do, Yeongtong-gu, Suwon-si, KOR
Woojung Bio Inc is engaged in the research and development of natural science and engineering. Its products include Gene Delivery, Antibody Production, Immunodeficiency model, Human-to-human model, Zika, Mers, Dengue, Influenza Virus Research, Influenza virus, vaccine studies, and Elegant Goettingen Mini Pig.

Woojung Bio Headlines

No Headlines